VERTEX PHARMACEUTICALS INC / MA Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) of $1.00 thousand for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses · last filed 2011-05-06
- VERTEX PHARMACEUTICALS INC / MA available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2011-03-31 was $1.00K.
- VERTEX PHARMACEUTICALS INC / MA available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2010-12-31 was $68.00K.
- VERTEX PHARMACEUTICALS INC / MA available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2010-09-30 was $4.00K.
- VERTEX PHARMACEUTICALS INC / MA available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for fiscal 2009 was $117.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2011-03-31 | $1.00K 10-Q · filed 2011-05-06 | $69.00K derived: sum of 2 quarters · filed 2011-05-06 | $73.00K derived: sum of 3 quarters · filed 2011-05-06 | |
| 2010-12-31 | $68.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2011-05-06 | $72.00K derived: sum of 2 quarters · filed 2011-05-06 | $73.00K 10-Q · filed 2011-05-06 | |
| 2010-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $5.00K 10-Q · filed 2010-10-28 | ||
| 2010-06-30 | $1.00K 10-Q · filed 2010-08-03 | |||
| 2009-12-31 | $117.00K 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |